Key Points
- Director Mauro Ferrari sold 8,750 shares on Nov. 28 at an average price of $56.39 for $493,412.50, trimming his holding by 11.29% to 68,764 shares valued at about $3.88M.
- Stock and analyst context: ARWR opened at $56.25 (52‑week range $9.57–$59.15) with a $7.64B market cap, was recently up ~6.7%, and carries an average analyst rating of "Moderate Buy" with a $52.78 target.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) Director Mauro Ferrari sold 8,750 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $56.39, for a total transaction of $493,412.50. Following the transaction, the director directly owned 68,764 shares in the company, valued at approximately $3,877,601.96. The trade was a 11.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Arrowhead Pharmaceuticals Stock Up 6.7%
ARWR stock opened at $56.25 on Tuesday. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $59.15. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. The firm has a 50-day simple moving average of $39.63 and a 200-day simple moving average of $26.34. The stock has a market capitalization of $7.64 billion, a P/E ratio of -43.95 and a beta of 1.27.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ARWR. iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $29,000. Salomon & Ludwin LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Federated Hermes Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $52,000. Smartleaf Asset Management LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 2,186.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company's stock worth $57,000 after buying an additional 1,618 shares during the last quarter. Finally, Virtus Advisers LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 62.61% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the company. Chardan Capital reissued a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Morgan Stanley raised their price objective on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an "equal weight" rating in a report on Wednesday, November 26th. B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Finally, Royal Bank Of Canada raised their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $52.78.
Read Our Latest Research Report on ARWR
Arrowhead Pharmaceuticals Company Profile
(
Get Free Report)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
